Key Takeaways
- Tesla (TSLA) shareholders have overwhelmingly approved a colossal pay package for CEO Elon Musk, potentially valued at up to $1 trillion, contingent on ambitious performance targets.
- President Donald Trump has announced significant deals with pharmaceutical giants Eli Lilly (LLY) and Novo Nordisk (NVO) to drastically reduce the costs of popular GLP-1 weight-loss drugs, with some oral doses potentially falling to around $150 per month.
- Trump also plans a one-year suspension of port crane duties and China ship fees, marking a key concession in an interim trade pact with Chinese President Xi Jinping.
- Australian finance giant Macquarie (MQG) reported a profit shortfall, attributed to tepid activity within its crucial commodities and global markets division.
Tesla (TSLA) shareholders have given their approval to a massive performance-based pay package for CEO Elon Musk, a deal that could be worth up to $1 trillion. The approval, reportedly with approximately 75% of votes in favor, comes with stringent conditions tied to the company's market capitalization, vehicle sales, and the deployment of robotaxis. This decision follows speculation that a rejection could have led to Musk's departure from the electric vehicle manufacturer.
In a move aimed at addressing rising healthcare costs, President Donald Trump has unveiled agreements with Eli Lilly (LLY) and Novo Nordisk (NVO) to lower the prices of highly popular GLP-1 weight-loss drugs. These deals, secured in exchange for relief from threatened tariffs, could see the cost of starting oral doses of GLP-1s, such as Ozempic, Wegovy, and Mounjaro, reduced to as low as $150 per month for eligible individuals on Medicare, Medicaid, or through the new direct-to-consumer website, TrumpRx.gov. This represents a drastic discount from current prices, which can exceed $1,000 monthly in the United States.
Further impacting global trade, President Trump announced a one-year pause on duties for port cranes and fees on Chinese ships. This temporary suspension of penalties targeting China's shipbuilding industry is a significant concession within an interim trade agreement reached with Chinese President Xi Jinping.
Meanwhile, the Australian financial services group Macquarie (MQG) has reported that its recent profit figures fell short of market expectations. The underperformance was primarily driven by subdued activity within its key commodities and global markets division, highlighting the challenges faced by the Australian finance giant in a fluctuating market environment.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.